The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
Stocktwits on MSN
Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...
AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...
Early-phase clinical trials, those first-in-human studies, are where years of research and millions in investment meet the ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
Ibex’s high-performance AI platform—already deployed across more than 50 health systems worldwide and used in collaboration ...
Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...
FDA and EMA have issued 10 guiding principles for AI in drug development with the intended goal of ensuring safety and ...
A new AI breakthrough could slash the time it takes to discover life-saving medicines, according to researchers in ...
Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback